-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

4044 Sokal Risk Score Is Superior to Hasford and EUTOS in Determining Survival Outcomes for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia PatientsClinically Relevant Abstract

Chronic Myeloid Leukemia: Therapy
Program: Oral and Poster Abstracts
Session: 632. Chronic Myeloid Leukemia: Therapy: Poster III
Monday, December 7, 2015, 6:00 PM-8:00 PM
Hall A, Level 2 (Orange County Convention Center)

Brian Gabriel Jiang1*, Dong-Wook Kim, M.D.2, Lee-Yung Shih, MD3, Charles Chuah4,5, Hein Than, MD4*, Ming-Chung Kuo, MD6*, HuiHua Li, PhD7*, John Carson Allen Jr., PhD8*, Lionel KY See9*, Bernard KC Yap9* and Yeow-Tee Goh, MBBS, MMed4,9

1Duke University School of Medicine, Durham, NC
2Department of Haematology, St. Mary’s Hospital, Seoul, South Korea
3Department of Hematology-Oncology, Chang Gung Memorial Hospital at Linkou, College of Medicine Chang Gung University, Taipei, Taiwan
4Department of Hematology, Singapore General Hospital, Singapore, Singapore
5Cancer & Stem Cell Biology Signature Research Program, Duke-NUS Graduate Medical School, Singapore, Singapore
6Chang Gung Memorial Hospital-Linkou and Chang Gung University, Taoyuan, Taiwan
7Health Services Research, Singapore, Singapore, Singapore
8Centre For Quantitative Medicine, Duke-NUS Graduate Medical School, Singapore, Singapore
9Duke-NUS Graduate Medical School, Singapore, Singapore

Despite being developed in eras when standard treatments for Chronic Phase Chronic Myeloid Leukemia (CP-CML) differ, Sokal, Hasford, and European Treatment and Outcome Study (EUTOS) scores each remain in use for predicting survival outcomes. The European LeukemiaNet (ELN) 2013 guidelines state that no one score is superior to the other. Furthermore, no studies have examined how a combination of scores may improve prognostic value. This retrospective, multicenter study compared the scores, individually and in combination, on predicting Overall Survival (OS), Progression-Free Survival (PFS) and Event-Free Survival (EFS) for CP-CML patients in Singapore General Hospital (Singapore), Seoul St. Mary’s Hospital (South Korea) and Chang Gung Memorial Hospital (Taiwan).

A total of 1222 newly diagnosed CP-CML patients (2013 ELN criteria) between July 1998 to December 2013 with follow-up period ≥18 months were reviewed. OS was defined as death from any cause, PFS was defined as transformation to accelerated or blastic phase and CML-related death. EFS was defined as failure according to the 2009 ELN criteria, treatment changes, progression, and death. Log likelihood ratio (LR) test of nested models was performed to compare dual combination scores with its individual components. Adequacy index was used to quantify the percentage of variation explained by each pair of scores. Harrell’s c-index was also calculated to evaluate the predictive ability of the scores. Linear contrast test was used to further stratify the individual risk groups in dual combination scores.

For OS, comparison of Sokal + EUTOS vs. EUTOS (LR 40.44 vs. 0.49) or Sokal + Hasford vs. Hasford (LR 31.78 vs. 11.81) showed that the combined model was significantly better than the individual models alone (p-value<0.01 for both). However, comparison of Sokal + EUTOS vs. Sokal or Sokal + Hasford vs. Sokal was not significantly better. Comparison of Hasford + EUTOS vs. EUTOS was significantly better (LR 21.37 vs. 0.92, p-value<0.01). Thus, for OS, the predictive ability order of the models are Sokal>Hasford>EUTOS, which are supported by Harrell's c-indices of 0.665, 0.591, 0.514, respectively. Similar predictive ability order for individual scores were also drawn for EFS (refer to table 1).

For PFS, comparison of Sokal + Hasford vs. Hasford showed the combined model was significantly better (LR 34.05 vs. 12.32, p-value<0.01). However comparison of Sokal + Hasford vs. Sokal was not significantly better, indicating the predictive ability of Sokal>Hasford, which is in agreement with the c-indices (0.620 vs. 0.569, respectively). Comparison of Sokal + EUTOS to either Sokal or EUTOS alone was both significantly better (LR 42.50 vs. 35.76, LR 42.50 vs. 20.33, respectively; p-value<0.01 for both). This is supported by similar c-indices for Sokal and EUTOS individually (0.620 and 0.621, respectively). However, in the combination of Sokal + EUTOS, Sokal explained 84.1% of the variation while EUTOS explained 47.8%. Thus, for PFS, the predictive ability of Sokal is superior to EUTOS or Hasford.

When analyzing dual combination scores, Sokal + EUTOS combined had the highest c-indices for OS, PFS and EFS (0.758, 0.705, 0.621) compared to EUTOS + Hasford and Sokal + Hasford. Linear contrast to rank Sokal + EUTOS in combination produced various valid paired orders, of which the order of SokalLow EUTOSLow, SokalIntermediate EUTOSLow, SokalIntermediate EUTOSHigh, SokalHigh EUTOSLow, SokalHigh EUTOSHighhad a hazard ratio of 4.47, 4.08, 2.26 for OS, PFS and EFS respectively (p-value<0.01 for all).

Contrary to the ELN 2013 guidelines that no single score is superior, our data shows that Sokal is superior in predicting OS, PFS and EFS in CP-CML. Dual score combinations are capable of improving prognostic ability, with Sokal + EUTOS in combination being the best to predict survival outcomes.

Table 1: Log likelihood ratios of dual combination scores versus individual scores.

Survival Outcome

Log Likelihood ratio (p-value)

EUTOS + SOKAL

EUTOS

SOKAL

OS

40.44

0.49 (<0.01)

38.66 (0.18)

PFS

42.50

20.33 (<0.01)

35.76 (<0.01)

EFS

74.66

11.32 (<0.01)

73.49 (0.28)

 

SOKAL + HASFORD

SOKAL

HASFORD

OS

31.78

31.31 (0.79)

11.81 (<0.01)

PFS

34.05

33.08 (0.61)

12.32 (<0.01)

EFS

57.94

55.85 (0.35)

32.24 (<0.01)

 

EUTOS + HASFORD

EUTOS

HASFORD

OS

21.37

0.92 (<0.01)

20.87 (0.48)

PFS

32.07

23.65 (<0.01)

20.22 (<0.01)

EFS

46.35

12.34 (<0.01)

44.17 (0.14)

Disclosures: Shih: Novartis: Research Funding . Chuah: Novartis: Honoraria ; Children International: Honoraria ; Bristol Meyers Squibb: Honoraria . Goh: Roche: Honoraria ; Janssen: Honoraria , Research Funding ; Gilead Sciences: Honoraria ; Sanofi: Honoraria ; Novartis: Honoraria , Research Funding ; Bristol-Myers Squibb: Honoraria ; Celgene: Honoraria .

*signifies non-member of ASH